The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

Cigna (CI) and UnitedHealth (UNH) significantly marked up prices for specialty generic drugs over a six-year period.

CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...

For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.

Margin expansion at Express Scripts, Caremark and Optum Rx increased by $336 million between 2017 and 2021, officials say.

The FTC released a 60-page report Tuesday targeting the biggest three pharmacy benefit managers, claiming the companies hiked the prices of specialty drugs to generate $7.3 billion in revenue from ...

Agency commissioners voted unanimously on Tuesday to publish the report, which makes a similar attack on the drug middlemen ...

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...